Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Head and Neck Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    October 2018
  1. KANAYAMA N, Kierkels RGJ, van der Schaaf A, Steenbakkers RJHM, et al
    External validation of a multifactorial normal tissue complication probability model for tube feeding dependence at 6months after definitive radiotherapy for head and neck cancer.
    Radiother Oncol. 2018 Oct 6. pii: S0167-8140(18)33496.
    PubMed     Text format     Abstract available


    September 2018
  2. HUANG XD, Zhou GQ, Lv JW, Zhou HQ, et al
    Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Radiother Oncol. 2018 Sep 27. pii: S0167-8140(18)33487.
    PubMed     Text format     Abstract available


  3. OVERGAARD J, Alsner J
    Effect of ESA as a modifier of radiotherapy in curative intended treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Radiother Oncol. 2018 Sep 21. pii: S0167-8140(18)33452.
    PubMed     Text format    


  4. BIAU J, Dunet V, Lapeyre M, Simon C, et al
    Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers.
    Radiother Oncol. 2018 Sep 8. pii: S0167-8140(18)33458.
    PubMed     Text format     Abstract available


    August 2018
  5. OU D, Adam J, Garberis I, Blanchard P, et al
    Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.
    Radiother Oncol. 2018 Aug 29. pii: S0167-8140(18)33451.
    PubMed     Text format     Abstract available


  6. DE VEIJ MESTDAGH PD, Janssen T, Lamers E, Carbaat C, et al
    SPECT/CT-guided elective nodal irradiation for head and neck cancer: Estimation of clinical benefits using NTCP models.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33422.
    PubMed     Text format     Abstract available


  7. LEGER S, Zwanenburg A, Pilz K, Zschaeck S, et al
    CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer.
    Radiother Oncol. 2018 Aug 4. pii: S0167-8140(18)33419.
    PubMed     Text format     Abstract available


  8. LI YJ, Luo Y, Xie XQ, Li P, et al
    The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: A prospective analysis.
    Radiother Oncol. 2018 Aug 3. pii: S0167-8140(18)33421.
    PubMed     Text format     Abstract available


    July 2018
  9. NOBLE DJ, Yeap PL, Seah SYK, Harrison K, et al
    Anatomical change during radiotherapy for head and neck cancer, and its effect on delivered dose to the spinal cord.
    Radiother Oncol. 2018 Jul 23. pii: S0167-8140(18)33396.
    PubMed     Text format     Abstract available


  10. VAN DEN BOSCH S, Dijkema T, Philippens MEP, Terhaard CHJ, et al
    Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of (18)F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting.
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33352.
    PubMed     Text format     Abstract available


  11. NAVRAN A, Heemsbergen W, Janssen T, Hamming-Vrieze O, et al
    The impact of margin reduction on outcome and toxicity in head and neck cancer patients treated with image-guided volumetric modulated arc therapy (VMAT).
    Radiother Oncol. 2018 Jul 10. pii: S0167-8140(18)33347.
    PubMed     Text format     Abstract available


    May 2018
  12. TAO Y, Faivre L, Laprie A, Boisselier P, et al
    Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.
    Radiother Oncol. 2018 May 18. pii: S0167-8140(18)30246.
    PubMed     Text format     Abstract available


  13. WINTER RM, Leibfarth S, Schmidt H, Zwirner K, et al
    Assessment of image quality of a radiotherapy-specific hardware solution for PET/MRI in head and neck cancer patients.
    Radiother Oncol. 2018 May 7. pii: S0167-8140(18)30209.
    PubMed     Text format     Abstract available


  14. MICHIELS S, Poels K, Crijns W, Delombaerde L, et al
    Volumetric modulated arc therapy of head-and-neck cancer on a fast-rotating O-ring linac: Plan quality and delivery time comparison with a C-arm linac.
    Radiother Oncol. 2018 May 5. pii: S0167-8140(18)30212.
    PubMed     Text format     Abstract available


  15. VAN DEN BOSCH S, Vogel WV, Raaijmakers CP, Dijkema T, et al
    Implications of improved diagnostic imaging of small nodal metastases in head and neck cancer: Radiotherapy target volume transformation and dose de-escalation.
    Radiother Oncol. 2018 May 3. pii: S0167-8140(18)30211.
    PubMed     Text format     Abstract available


    April 2018
  16. MURTHY V, Lewis S, Kannan S, Khadanga CR, et al
    Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study.
    Radiother Oncol. 2018 Apr 30. pii: S0167-8140(18)30113.
    PubMed     Text format     Abstract available


  17. GREGOIRE V, Grau C
    In reply to "A Long-Awaited Guideline for the Delineation of Primary Tumor in Head and Neck Cancer, and a Few Concerns about It" by Sezin Yuce Sari et al.
    Radiother Oncol. 2018 Apr 27. pii: S0167-8140(18)30175.
    PubMed     Text format    


  18. YUCE SARI S, Yeginer M, Cengiz M
    A long-awaited guideline for the delineation of primary tumor in head and neck cancer, and a few concerns about it.
    Radiother Oncol. 2018 Apr 24. pii: S0167-8140(18)30177.
    PubMed     Text format    


    March 2018
  19. TAN TH, Soon YY, Cheo T, Ho F, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
    Radiother Oncol. 2018 Mar 16. pii: S0167-8140(18)30123.
    PubMed     Text format     Abstract available


  20. SHURYAK I, Hall EJ, Brenner DJ
    Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications.
    Radiother Oncol. 2018 Mar 10. pii: S0167-8140(18)30098.
    PubMed     Text format     Abstract available


  21. FANG P, Jiang W, Davuluri R, Xu C, et al
    High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer.
    Radiother Oncol. 2018 Mar 9. pii: S0167-8140(18)30117.
    PubMed     Text format     Abstract available


  22. OVERGAARD J, Hoff CM, Hansen HS, Specht L, et al
    DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Radiother Oncol. 2018 Mar 6. pii: S0167-8140(18)30105.
    PubMed     Text format     Abstract available


  23. HE J, Cai L, Chen Y, He Y, et al
    Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway.
    Radiother Oncol. 2018 Mar 5. pii: S0167-8140(18)30063.
    PubMed     Text format     Abstract available


  24. AMPFERL R, Rodemann HP, Mayer C, Hofling TTA, et al
    Glucose starvation impairs DNA repair in tumour cells selectively by blocking histone acetylation.
    Radiother Oncol. 2018;126:465-470.
    PubMed     Text format     Abstract available


    January 2018
  25. IQBAL MS, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A survey of UK national practice.
    Radiother Oncol. 2018 Jan 20. pii: S0167-8140(17)32734.
    PubMed     Text format    


  26. SHAHID IQBAL M, Kelly C, Kovarik J, Goranov B, et al
    Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review.
    Radiother Oncol. 2018 Jan 19. pii: S0167-8140(17)32766.
    PubMed     Text format     Abstract available


  27. ADENIS A, Castan F, Conroy T
    Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32773.
    PubMed     Text format    


  28. CHEN Y, Wang J
    Concurrent chemoradiotherapy alone is feasible for esophageal squamous cell carcinoma patients not suitable for surgery.
    Radiother Oncol. 2018 Jan 10. pii: S0167-8140(17)32774.
    PubMed     Text format    


  29. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Reply to Elicin et al.
    Radiother Oncol. 2018 Jan 4. pii: S0167-8140(17)32770.
    PubMed     Text format    


  30. ZUKAUSKAITE R, Hansen CR, Grau C, Samsoe E, et al
    Local recurrences after curative IMRT for HNSCC: Effect of different GTV to high-dose CTV margins.
    Radiother Oncol. 2018;126:48-55.
    PubMed     Text format     Abstract available


  31. GREGOIRE V, Evans M, Le QT, Bourhis J, et al
    Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Onc
    Radiother Oncol. 2018;126:3-24.
    PubMed     Text format     Abstract available


  32. HANSEN CR, Johansen J, Samsoe E, Andersen E, et al
    Consequences of introducing geometric GTV to CTV margin expansion in DAHANCA contouring guidelines for head and neck radiotherapy.
    Radiother Oncol. 2018;126:43-47.
    PubMed     Text format     Abstract available


  33. LASSEN P, Lacas B, Pignon JP, Trotti A, et al
    Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project.
    Radiother Oncol. 2018;126:107-115.
    PubMed     Text format     Abstract available


  34. VAN DIJK LV, Noordzij W, Brouwer CL, Boellaard R, et al
    (18)F-FDG PET image biomarkers improve prediction of late radiation-induced xerostomia.
    Radiother Oncol. 2018;126:89-95.
    PubMed     Text format     Abstract available


    December 2017
  35. ZHANG Y, Li WF, Liu X, Chen L, et al
    Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.
    Radiother Oncol. 2017 Dec 16. pii: S0167-8140(17)32756.
    PubMed     Text format     Abstract available


  36. SHIRAISHI Y, Fang P, Xu C, Song J, et al
    Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Radiother Oncol. 2017 Dec 13. pii: S0167-8140(17)32751.
    PubMed     Text format     Abstract available


  37. KAMAL M, Rosenthal DI, Volpe S, Goepfert RP, et al
    Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.
    Radiother Oncol. 2017 Dec 8. pii: S0167-8140(17)32691.
    PubMed     Text format     Abstract available


    November 2017
  38. LEE AW, Ng WT, Pan JJ, Poh SS, et al
    International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
    Radiother Oncol. 2017 Nov 15. pii: S0167-8140(17)32686.
    PubMed     Text format     Abstract available


  39. BOGOWICZ M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, et al
    Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.
    Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663.
    PubMed     Text format     Abstract available


  40. TAKAHASHI N, Umezawa R, Takanami K, Yamamoto T, et al
    Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Nov 3. pii: S0167-8140(17)32659.
    PubMed     Text format     Abstract available


    October 2017
  41. CEREDA E, Cappello S, Colombo S, Klersy C, et al
    Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy.
    Radiother Oncol. 2017 Oct 27. pii: S0167-8140(17)32655.
    PubMed     Text format     Abstract available


  42. OU D, Garberis I, Adam J, Blanchard P, et al
    Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Radiother Oncol. 2017 Oct 24. pii: S0167-8140(17)32647.
    PubMed     Text format     Abstract available


  43. DE-COLLE C, Menegakis A, Monnich D, Welz S, et al
    SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
    Radiother Oncol. 2017 Oct 20. pii: S0167-8140(17)32648.
    PubMed     Text format     Abstract available


  44. RAO AD, Coquia S, De Jong R, Gourin C, et al
    Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.
    Radiother Oncol. 2017 Oct 3. pii: S0167-8140(17)32584.
    PubMed     Text format     Abstract available


  45. COX S, Hurt C, Grenader T, Mukherjee S, et al
    The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017;125:154-159.
    PubMed     Text format     Abstract available


  46. LARUE RTHM, Van De Voorde L, van Timmeren JE, Leijenaar RTH, et al
    4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers.
    Radiother Oncol. 2017;125:147-153.
    PubMed     Text format     Abstract available


    September 2017
  47. MICHIELS S, Barragan AM, Souris K, Poels K, et al
    Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Radiother Oncol. 2017 Sep 23. pii: S0167-8140(17)32568.
    PubMed     Text format     Abstract available


  48. WOPKEN K, Bijl HP, Langendijk JA
    Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
    Radiother Oncol. 2017 Sep 21. pii: S0167-8140(17)32545.
    PubMed     Text format     Abstract available


  49. CHANG CL, Tsai HC, Lin WC, Chang JH, et al
    Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Sep 15. pii: S0167-8140(17)32548.
    PubMed     Text format     Abstract available


  50. SHIRAISHI Y, Xu C, Yang J, Komaki R, et al
    Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Radiother Oncol. 2017 Sep 13. pii: S0167-8140(17)32550.
    PubMed     Text format     Abstract available


  51. KOI L, Lock S, Linge A, Thurow C, et al
    EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
    Radiother Oncol. 2017;124:496-503.
    PubMed     Text format     Abstract available


  52. SCHNEIDER K, Bol V, Gregoire V
    Lack of differences in radiation-induced immunogenicity parameters between HPV-positive and HPV-negative human HNSCC cell lines.
    Radiother Oncol. 2017;124:411-417.
    PubMed     Text format     Abstract available


    August 2017
  53. YANG H, Chen X, Lin S, Rong J, et al
    Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Radiother Oncol. 2017 Aug 29. pii: S0167-8140(17)32479.
    PubMed     Text format     Abstract available


  54. LOCK S, Perrin R, Seidlitz A, Bandurska-Luque A, et al
    Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Radiother Oncol. 2017 Aug 23. pii: S0167-8140(17)32517.
    PubMed     Text format     Abstract available


  55. FERRIS MJ, Zhong J, Switchenko JM, Higgins KA, et al
    Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
    Radiother Oncol. 2017 Aug 18. pii: S0167-8140(17)32515.
    PubMed     Text format     Abstract available


  56. TONLAAR N, Galoforo S, Thibodeau BJ, Ahmed S, et al
    Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32501.
    PubMed     Text format     Abstract available


  57. HAWKINS PG, Lee JY, Mao Y, Li P, et al
    Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32502.
    PubMed     Text format     Abstract available


  58. HUIZING FJ, Hoeben BAW, Franssen G, Lok J, et al
    Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
    Radiother Oncol. 2017 Aug 5. pii: S0167-8140(17)32484.
    PubMed     Text format     Abstract available


  59. HOSNI A, McMullen C, Huang SH, Xu W, et al
    Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.
    Radiother Oncol. 2017;124:225-231.
    PubMed     Text format     Abstract available



  60. Dose-volume correlates of mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated radiotherapy: Results from a case-matched comparison.
    Radiother Oncol. 2017;124:232-239.
    PubMed     Text format     Abstract available


  61. MAVROIDIS P, Price A, Fried D, Kostich M, et al
    Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Radiother Oncol. 2017;124:240-247.
    PubMed     Text format     Abstract available


  62. JURADO-BRUGGEMAN D, Hernandez V, Saez J, Navarro D, et al
    Multi-centre audit of VMAT planning and pre-treatment verification.
    Radiother Oncol. 2017;124:302-310.
    PubMed     Text format     Abstract available


  63. DELANEY AR, Dahele M, Tol JP, Kuijper IT, et al
    Using a knowledge-based planning solution to select patients for proton therapy.
    Radiother Oncol. 2017;124:263-270.
    PubMed     Text format     Abstract available


    July 2017
  64. MOHAMED ASR, Cardenas CE, Garden AS, Awan MJ, et al
    Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Radiother Oncol. 2017 Jul 31. pii: S0167-8140(17)32476.
    PubMed     Text format     Abstract available


  65. ZHAI TT, van Dijk LV, Huang BT, Lin ZX, et al
    Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters.
    Radiother Oncol. 2017 Jul 29. pii: S0167-8140(17)32472.
    PubMed     Text format     Abstract available


  66. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.
    Radiother Oncol. 2017 Jul 26. pii: S0167-8140(17)32470.
    PubMed     Text format     Abstract available


  67. NEVENS D, Duprez F, Daisne JF, De Neve W, et al
    Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.
    Radiother Oncol. 2017 Jul 24. pii: S0167-8140(17)32456.
    PubMed     Text format    


  68. RASSAMEGEVANON T, Lock S, Range U, Krause M, et al
    Tumor heterogeneity determined with a gammaH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models.
    Radiother Oncol. 2017 Jul 21. pii: S0167-8140(17)32447.
    PubMed     Text format     Abstract available


  69. XI M, Xu C, Liao Z, Hofstetter WL, et al
    The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Jul 4. pii: S0167-8140(17)30428.
    PubMed     Text format     Abstract available


  70. JIN P, Hulshof MCCM, van Wieringen N, Bel A, et al
    Interfractional variability of respiration-induced esophageal tumor motion quantified using fiducial markers and four-dimensional cone-beam computed tomography.
    Radiother Oncol. 2017;124:147-154.
    PubMed     Text format     Abstract available


    June 2017
  71. ZHANG D, Zhang W, Liu W, Mao Y, et al
    Human papillomavirus infection increases the chemoradiation response of esophageal squamous cell carcinoma based on P53 mutation.
    Radiother Oncol. 2017 Jun 21. pii: S0167-8140(17)30408.
    PubMed     Text format     Abstract available


  72. MCLAY M, Stedford A, Yurkowski E, Matlock S, et al
    Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients treated in a provincially coordinated radiotherapy program.
    Radiother Oncol. 2017 Jun 15. pii: S0167-8140(17)30401.
    PubMed     Text format     Abstract available


  73. BIRD D, Patel C, Scarsbrook AF, Cosgrove V, et al
    Evaluation of clinical target volume expansion required for involved site neck radiotherapy for lymphoma to account for the absence of a pre-chemotherapy PET-CT in the radiotherapy treatment position.
    Radiother Oncol. 2017 Jun 6. pii: S0167-8140(17)30378.
    PubMed     Text format     Abstract available


  74. ZHANG W, Zhang X, Yang P, Blanchard P, et al
    Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
    Radiother Oncol. 2017;123:401-405.
    PubMed     Text format     Abstract available


  75. IKAWA H, Koto M, Takagi R, Ebner DK, et al
    Prognostic factors of adenoid cystic carcinoma of the head and neck in carbon-ion radiotherapy: The impact of histological subtypes.
    Radiother Oncol. 2017;123:387-393.
    PubMed     Text format     Abstract available


  76. CHEN AM, Chin R, Beron P, Yoshizaki T, et al
    Inadequate target volume delineation and local-regional recurrence after intensity-modulated radiotherapy for human papillomavirus-positive oropharynx cancer.
    Radiother Oncol. 2017;123:412-418.
    PubMed     Text format     Abstract available


    May 2017
  77. KOPPENHAGEN P, Dickreuter E, Cordes N
    Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
    Radiother Oncol. 2017 May 31. pii: S0167-8140(17)30375.
    PubMed     Text format     Abstract available


  78. CHEN J, Cai W, Zheng X, Chen Y, et al
    The pattern of cervical lymph node metastasis in thoracic esophageal squamous cell carcinoma may affect the target decision for definitive radiotherapy.
    Radiother Oncol. 2017 May 24. pii: S0167-8140(17)30152.
    PubMed     Text format     Abstract available


  79. LAI TY, Wang TH, Liu CJ, Chao TF, et al
    Risk factors for osteonecrosis of the jaw in oral cancer patients after surgery and eventual adjuvant treatment: The potential role of chemotherapy.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30362.
    PubMed     Text format     Abstract available


  80. FAN CY, Lin CS, Chao HL, Huang WY, et al
    Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30367.
    PubMed     Text format     Abstract available


  81. CHRISTIAENS M, Collette S, Overgaard J, Gregoire V, et al
    Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
    Radiother Oncol. 2017 May 4. pii: S0167-8140(17)30160.
    PubMed     Text format     Abstract available


    April 2017
  82. LIN SH, Merrell KW, Shen J, Verma V, et al
    Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.
    Radiother Oncol. 2017 Apr 25. pii: S0167-8140(17)30154.
    PubMed     Text format     Abstract available


  83. WELZ S, Monnich D, Pfannenberg C, Nikolaou K, et al
    Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
    Radiother Oncol. 2017 Apr 20. pii: S0167-8140(17)30144.
    PubMed     Text format     Abstract available


  84. RUSTHOVEN CG, Lanning RM, Jones BL, Amini A, et al
    Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
    Radiother Oncol. 2017 Apr 19. pii: S0167-8140(17)30130.
    PubMed     Text format     Abstract available


  85. ZHU H, Song H, Chen G, Yang X, et al
    eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Apr 18. pii: S0167-8140(17)30140.
    PubMed     Text format     Abstract available


  86. YAMASHITA H, Abe O, Nakagawa K
    Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
    Radiother Oncol. 2017 Apr 17. pii: S0167-8140(17)30141.
    PubMed     Text format    


  87. WU B, Kusters M, Kunze-Busch M, Dijkema T, et al
    Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).
    Radiother Oncol. 2017;123:57-62.
    PubMed     Text format     Abstract available


    March 2017
  88. NEVENS D, Duprez F, Daisne JF, Schatteman J, et al
    Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer.
    Radiother Oncol. 2017 Mar 22. pii: S0167-8140(17)30099.
    PubMed     Text format     Abstract available


  89. NAKAMURA N, Zenda S, Tahara M, Okano S, et al
    Proton beam therapy for olfactory neuroblastoma.
    Radiother Oncol. 2017;122:368-372.
    PubMed     Text format     Abstract available


    February 2017
  90. BERTHON B, Evans M, Marshall C, Palaniappan N, et al
    Head and neck target delineation using a novel PET automatic segmentation algorithm.
    Radiother Oncol. 2017;122:242-247.
    PubMed     Text format     Abstract available


  91. VAN LOON J, Even AJ, Aerts HJ, Ollers M, et al
    PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
    Radiother Oncol. 2017;122:267-273.
    PubMed     Text format     Abstract available


  92. BUSCH CJ, Kroger MS, Jensen J, Kriegs M, et al
    G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Radiother Oncol. 2017;122:260-266.
    PubMed     Text format     Abstract available


  93. KOVACS G, Martinez-Monge R, Budrukkar A, Guinot JL, et al
    GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update - Improvement by cross sectional imaging based treatment planning and stepping source technology.
    Radiother Oncol. 2017;122:248-254.
    PubMed     Text format     Abstract available


  94. HAMMING-VRIEZE O, van Kranen SR, Heemsbergen WD, Lange CA, et al
    Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy.
    Radiother Oncol. 2017;122:224-228.
    PubMed     Text format     Abstract available


  95. GRONLUND E, Johansson S, Montelius A, Ahnesjo A, et al
    Dose painting by numbers based on retrospectively determined recurrence probabilities.
    Radiother Oncol. 2017;122:236-241.
    PubMed     Text format     Abstract available


  96. SODERSTROM K, Nilsson P, Laurell G, Zackrisson B, et al
    Dysphagia - Results from multivariable predictive modelling on aspiration from a subset of the ARTSCAN trial.
    Radiother Oncol. 2017;122:192-199.
    PubMed     Text format     Abstract available


  97. NEVENS D, Duprez F, Daisne JF, Laenen A, et al
    Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for late fibrosis.
    Radiother Oncol. 2017;122:212-216.
    PubMed     Text format     Abstract available


  98. VAN DIJK LV, Brouwer CL, van der Schaaf A, Burgerhof JG, et al
    CT image biomarkers to improve patient-specific prediction of radiation-induced xerostomia and sticky saliva.
    Radiother Oncol. 2017;122:185-191.
    PubMed     Text format     Abstract available


  99. VAN DIJK LV, Langendijk JA, Sijtsema NM, Steenbakkers RJHM, et al
    Reply letter to "Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis".
    Radiother Oncol. 2017;122:322.
    PubMed     Text format    


  100. NARDONE V, Tini P, Nioche C, Biondi M, et al
    Texture analysis of parotid gland as a predictive factor of radiation induced xerostomia: A subset analysis.
    Radiother Oncol. 2017;122:321.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: